Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Table 3

TAC level in the urine in BC patients and control group.

Groups	TAC in urine [mM/mM cr.]
	Mean	SD	p-value
BC	1.26	0.63	p≤0.001; BC vs C
C	2.05	0.46
NMIBC	1.26	1.23	p=0.484; NMIBC vs MIBC
MIBC	1.36	0.60
LG	1.22	0.54	p=0.621; LG vs HG
HG	1.33	0.73
M	1.28	0.65	p=0.733; M vs W
W	1.20	0.57
Non-smoking patients	1.36	0.56	p=0.593; non-smoking vs smoking
Smoking patients	1.24	0.65

BC: patients group; C: control group; NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; M: men; W: women; SD: standard deviation; p: statistically significant difference.